All You Need to Know About Contineum Therapeutics, Inc. (CTNM) Rating Upgrade to BuyZacks Investment Research · Oct 12, 2026
Why Is Contineum Therapeutics Stock Falling Monday?Benzinga · Oct 12, 2026
48,108 Contineum Therapeutics, Inc. $CTNM Shares Sold by Squarepoint Ops LLCDefense World · Sep 25, 2026
Contineum Therapeutics (NASDAQ:CTNM) Trading Down 9.9% After Analyst DowngradeDefense World · Sep 16, 2026
Johnson & Johnson Partner Contineum Slides as Depression Drug FailsBenzinga · Sep 15, 2026
Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive DisorderBusiness Wire · Sep 14, 2026Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 30, 2026 | -$0.45 | -$0.40 | Beat |
| May 5, 2026 | -$0.55 | -$0.39 | Beat |
| Mar 5, 2026 | -$0.50 | -$0.49 | Beat |
| Oct 30, 2025 | -$0.58 | -$0.45 | Beat |
| Aug 5, 2025 | -$0.56 | -$0.62 | Miss |
| May 14, 2025 | -$0.56 | -$0.62 | Miss |